URGN Q3 2017 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M

Gross Profit

$8M96.2% margin

Operating Income

-$303,000-3.9% margin

Net Income

-$298,000-3.8% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$3M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$81M

Total Liabilities

$5M

Stockholders' Equity

$76M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$0	—
Gross Profit	$8M	$0	—
Operating Income	-$303,000	-$6M	+95.0%
Net Income	-$298,000	-$8M	+96.3%